{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=64",
    "query": {
      "intervention": "Dose Level -1",
      "page": 64
    },
    "page_size": 10
  },
  "pagination": {
    "page": 64,
    "page_size": 10,
    "total_count": 29129,
    "total_pages": 2913,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=65&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+Level+-1&page=63&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T09:52:49.082Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02735707",
      "title": "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Tract Diseases",
        "Influenza (Pandemic)",
        "Influenza",
        "Community Acquired Pneumonia",
        "Community Acquired Pneumonia (CAP)",
        "Community Acquired Pneumonia, Severe",
        "COVID-19",
        "Respiratory Tract Infection Acute",
        "Respiratory Tract Infections (RTI)",
        "SARS CoV 2 Infection"
      ],
      "interventions": [
        {
          "name": "Ceftriaxone + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin or Levofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Piperacillin-tazobactam + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Ceftaroline + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin-clavulanate + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Standard course macrolide",
          "type": "DRUG"
        },
        {
          "name": "Extended course macrolide",
          "type": "DRUG"
        },
        {
          "name": "No systemic corticosteroid",
          "type": "OTHER"
        },
        {
          "name": "Fixed-duration Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Shock-dependent hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration higher dose Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for influenza",
          "type": "OTHER"
        },
        {
          "name": "Five-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir",
          "type": "DRUG"
        },
        {
          "name": "No antiviral agent for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Lopinavir / Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine + lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Ivermectin",
          "type": "DRUG"
        },
        {
          "name": "No immune modulation for COVID-19",
          "type": "OTHER"
        },
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Anakinra",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Local standard venous thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "Conventional low dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Intermediate dose thromboprophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Continuation of therapeutic dose anticoagulation",
          "type": "DRUG"
        },
        {
          "name": "No immunoglobulin",
          "type": "OTHER"
        },
        {
          "name": "Convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Delayed administration of convalescent plasma",
          "type": "BIOLOGICAL"
        },
        {
          "name": "No vitamin C",
          "type": "OTHER"
        },
        {
          "name": "Vitamin C",
          "type": "DRUG"
        },
        {
          "name": "No antiplatelet",
          "type": "OTHER"
        },
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "P2Y12 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "No simvastatin",
          "type": "OTHER"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Eritoran",
          "type": "DRUG"
        },
        {
          "name": "Apremilast",
          "type": "DRUG"
        },
        {
          "name": "Clinician-preferred mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "Protocolised mechanical ventilation strategy",
          "type": "PROCEDURE"
        },
        {
          "name": "No renin-angiotensin system inhibitor",
          "type": "OTHER"
        },
        {
          "name": "Angiotensin converting enzyme inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Angiotensin Receptor Blockers",
          "type": "DRUG"
        },
        {
          "name": "ARB + DMX-200",
          "type": "DRUG"
        },
        {
          "name": "No cysteamine",
          "type": "OTHER"
        },
        {
          "name": "Cysteamine",
          "type": "DRUG"
        },
        {
          "name": "Fixed-duration dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Baloxavir Marboxil",
          "type": "DRUG"
        },
        {
          "name": "Five-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "Ten-days oseltamivir + baloxavir marboxil",
          "type": "DRUG"
        },
        {
          "name": "No endothelial modulator",
          "type": "OTHER"
        },
        {
          "name": "Imatinib",
          "type": "DRUG"
        },
        {
          "name": "No Immune Modulator for Influenza",
          "type": "OTHER"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Nirmatrelvir/ritonavir + remdesivir",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin-clavulanate + Ceftazidime + Macrolide",
          "type": "DRUG"
        },
        {
          "name": "Meropenem + Macrolide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "UMC Utrecht",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "28 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "28 Days and older"
      },
      "enrollment_count": 20000,
      "start_date": "2016-04-11",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 11,
      "location_summary": "Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02735707"
    },
    {
      "nct_id": "NCT03218592",
      "title": "ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV/AIDS"
      ],
      "interventions": [
        {
          "name": "Maraviroc Pill",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir Pill",
          "type": "DRUG"
        },
        {
          "name": "Truvada Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-06-28",
      "completion_date": "2018-12-07",
      "has_results": true,
      "last_update_posted_date": "2019-11-22",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03218592"
    },
    {
      "nct_id": "NCT01737892",
      "title": "Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation",
          "type": "DRUG"
        },
        {
          "name": "Arm C-Epinephrine Inhalation Aerosol CFC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amphastar Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "18 Years to 30 Years"
      },
      "enrollment_count": 21,
      "start_date": "2012-11",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2016-03-17",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01737892"
    },
    {
      "nct_id": "NCT01157364",
      "title": "Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "bimatoprost 20 µg generation 2",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 15 µg generation 2",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 10 µg generation 2",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 6 µg generation 2",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 15 µg generation 1",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 10 µg generation 1",
          "type": "DRUG"
        },
        {
          "name": "bimatoprost 0.03%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2010-09-23",
      "completion_date": "2016-08-09",
      "has_results": true,
      "last_update_posted_date": "2020-03-30",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 36,
      "location_summary": "Artesia, California • La Jolla, California • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01157364"
    },
    {
      "nct_id": "NCT01081132",
      "title": "Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Attention-Deficit/Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Extended-release Guanfacine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 314,
      "start_date": "2011-09-19",
      "completion_date": "2013-05-16",
      "has_results": true,
      "last_update_posted_date": "2021-06-28",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 54,
      "location_summary": "Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01081132"
    },
    {
      "nct_id": "NCT02613598",
      "title": "Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hodgkin's Lymphoma",
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-05-12",
      "completion_date": "2021-06-07",
      "has_results": false,
      "last_update_posted_date": "2021-12-20",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02613598"
    },
    {
      "nct_id": "NCT01352793",
      "title": "A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis, Meningococcal"
      ],
      "interventions": [
        {
          "name": "rLP2086 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 5715,
      "start_date": "2012-11",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2015-03-11",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 39,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01352793"
    },
    {
      "nct_id": "NCT07195916",
      "title": "A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "INCA036873",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2026-01-08",
      "completion_date": "2028-08-18",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 8,
      "location_summary": "Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07195916"
    },
    {
      "nct_id": "NCT01440816",
      "title": "IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tavokinogene Telseplasmid (tavo)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "OncoSec Medical System (OMS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "OncoSec Medical Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2012-01-03",
      "completion_date": "2015-04-10",
      "has_results": true,
      "last_update_posted_date": "2023-05-15",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01440816"
    },
    {
      "nct_id": "NCT07076121",
      "title": "A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Navlimetostat",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 470,
      "start_date": "2025-10-23",
      "completion_date": "2029-05-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-11-19T09:52:49.082Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Springdale, Arkansas + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07076121"
    }
  ]
}